kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Mouse LDLR Protein, 2x500ug  

Recombinant Mouse LDLR Protein, 2x500ug

Recombinant Mouse LDLR Protein (Mouse LDLR) Ala 22 - Arg 790 was produced in human 293 cells (HEK293), His Tag

Synonyms: Recombinant Mouse Protein, LDLR,FH,FHC,LDLCQ2

More details


Availability: within 7 days

1 800,00 €

Low-Density Lipoprotein (LDL) Receptor is also known as LDLR, FH, FHC, LDLCQ2, and is a mosaic protein of ~840 amino acids (after removal of signal peptide) that mediates the endocytosis of cholesterol-rich LDL. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles. The receptor also recognizes the apoE protein found in chylomicron remnants and VLDL remnants (IDL). It belongs to the Low density lipoprotein receptor gene family. LDL receptor complexes are present in clathrin-coated pits (or buds) on the cell surface, which when bound to LDL-cholesterol via adaptin, are pinched off to form clathrin-coated vesicles inside the cell. This allows LDL-cholesterol to be bound and internalized in a process known as endocytosis and prevents the LDL just diffusing around the membrane surface. This occurs in all nucleated cells (not erythrocytes), but mainly in the liver which removes ~70% of LDL from the circulation. Synthesis of receptors in the cell is regulated by the level of free intracellular cholesterol; if it is in excess for the needs of the cell then the transcription of the receptor gene will be inhibited. LDL receptors are translated by ribosomes on the endoplasmic reticulum and are modified by the Golgi apparatus before travelling in vesicles to the cell surface. LDL is directly involved in the development of atherosclerosis, due to accumulation of LDL-cholesterol in the blood. Atherosclerosis is the process responsible for the majority of cardiovascular diseases.

Recombinant Mouse LDL R, His Tag (LDR-M52H8) is expressed from human 293 cells (HEK293). It contains AA Ala 22 - Arg 790 (Accession # NP_034830).
Predicted N-terminus: Ala 22

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 86.2 kDa. The protein migrates as 120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose are added as protectants before lyophilization.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet.

Clinical and Translational Updates

(1) "PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients"
Huang, Xiao, Peng et al
Psychopharmacology (Berl) (2022)
(2) "Executive functioning and serum lipid fractions in Parkinson's disease-a possible sex-effect: the PACOS study"
Luca, Monastero, Cicero et al
J Neural Transm (Vienna) (2022)
(3) "Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes"
Waluś-Miarka, Kapusta, Miarka et al
Cardiovasc Ther (2021) 2021, 7956161
Showing 1-3 of 9040 papers.